Article

Mutation in Abl kinase with altered drug binding kinetics indicates a novel mechanism of imatinib resistance

2021-06-28

Abstract excerpt

Protein kinase inhibitors are potent anti-cancer therapeutics (1). For example, the Bcr-Abl kinase inhibitor imatinib decreases mortality for Chronic Myeloid Leukemia (CML) by 80% (2, 3), but 22-41% of patients acquire resistance to imatinib (4). About 70% of relapsed patients harbor mutations in the Bcr-Abl kinase domain (5), in which more than a hundred different mutations have been identified (6–8). Some mutati...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7d8f2c92-d33c-5c0f-a9fc-9579bb2f1fc5
DOI: 10.1101/2021.06.28.449968

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Mutation in Abl kinase with altered drug binding kinetics indicates a novel mechanism of imatinib resistanceDOI 10.1101/2021.06.28.449968Read

Mutation in Abl kinase with altered drug-binding kinetics indicates a novel mechanism of imatinib resistance.Semantic proximity Read

Resistance in the land of molecular cancer therapeutics.Semantic proximity Read

Overriding imatinib resistance with a novel ABL kinase inhibitor.Semantic proximity Read

Mechanisms of drug resistance in kinasesSemantic proximity Read

Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.Semantic proximity Read

Mechanisms and implications of imatinib resistance mutations in BCR-ABLSemantic proximity Read

Cumulative mechanism of several major imatinib-resistant mutations in Abl kinaseSemantic proximity Read

Mutation Profiling of BCR-ABL Kinase Domain in Chronic Myeloid Leukaemia Patients with Imatinib ResistanceSemantic proximity Read

Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistanceSemantic proximity Read

Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical RelevanceSemantic proximity Read

Resistance to imatinib: mutations and beyond.Semantic proximity Read

Novel Agents in CML Therapy: Tyrosine Kinase Inhibitors and BeyondSemantic proximity Read